1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, S.-J. | - |
dc.contributor.author | Kim, J.-S. | - |
dc.contributor.author | Hong, S.J. | - |
dc.contributor.author | Lim, D.-S. | - |
dc.contributor.author | Lee, S.-Y. | - |
dc.contributor.author | Yun, K.H. | - |
dc.contributor.author | Park, J.-K. | - |
dc.contributor.author | Kang, W.C. | - |
dc.contributor.author | Kim, Y.H. | - |
dc.contributor.author | Yoon, H.-J. | - |
dc.contributor.author | Won, H. | - |
dc.contributor.author | Nam, C.-M. | - |
dc.contributor.author | Ahn, C.-M. | - |
dc.contributor.author | Kim, B.-K. | - |
dc.contributor.author | Ko, Y.-G. | - |
dc.contributor.author | Choi, D. | - |
dc.contributor.author | Jang, Y. | - |
dc.contributor.author | Hong, M.-K. | - |
dc.contributor.author | One-Month DAPT Investigators | - |
dc.date.accessioned | 2023-03-08T10:39:04Z | - |
dc.date.available | 2023-03-08T10:39:04Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 1936-8798 | - |
dc.identifier.issn | 1876-7605 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/62255 | - |
dc.description.abstract | Objectives: The aim of this study was to determine whether 1 month of dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy after polymer-free drug-coated stent (PF-DCS) implantation is noninferior to 6 to 12 months of DAPT after biodegradable-polymer drug-eluting stent (BP-DES) implantation. Background: It is necessary to determine the optimal minimal duration of DAPT followed by aspirin monotherapy after percutaneous coronary intervention (PCI). Methods: In this trial, 3,020 patients with coronary artery disease considered for PCI for noncomplex lesions were randomized to 1-month DAPT after PF-DCS (n = 1,507) or 6- to 12-month DAPT after BP-DES (n = 1,513). The primary endpoint was the 1-year composite of cardiac death, nonfatal myocardial infarction, target vessel revascularization, stroke, or major bleeding (noninferiority hypothesis margin of 3%). Results: The primary endpoint occurred in 88 patients (5.9%) in the 1-month DAPT after PF-DCS group and 98 patients (6.5%) in the 6- to 12-month DAPT after BP-DES group (absolute difference −0.7%; upper limit of 1-sided 97.5% confidence interval: 1.33%; P < 0.001 for noninferiority). The occurrence of major bleeding was not different (1.7% vs 2.5%; P = 0.136). There was no difference in the occurrence of stent thrombosis (0.7% vs 0.8%; P = 0.842). Conclusions: Among patients who underwent PCI for noncomplex lesions, 1-month DAPT followed by aspirin monotherapy after PF-DCS implantation was noninferior to 6- to 12-month DAPT after BP-DES implantation for the 1-year composite of cardiovascular events or major bleeding. The present findings need to be interpreted in the setting of different types of stents according to antiplatelet strategy. (A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-Eluting Stent Implantation; NCT02513810) © 2021 American College of Cardiology Foundation | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Inc. | - |
dc.title | 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jcin.2021.06.003 | - |
dc.identifier.bibliographicCitation | JACC: Cardiovascular Interventions, v.14, no.16, pp 1801 - 1811 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000697573200014 | - |
dc.identifier.scopusid | 2-s2.0-85112004316 | - |
dc.citation.endPage | 1811 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 1801 | - |
dc.citation.title | JACC: Cardiovascular Interventions | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | antiplatelet therapy | - |
dc.subject.keywordAuthor | drug-eluting stent(s) | - |
dc.subject.keywordAuthor | percutaneous coronary intervention | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | BARE-METAL STENTS | - |
dc.subject.keywordPlus | ELUTING STENTS | - |
dc.subject.keywordPlus | FOCUSED UPDATE | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | ANGIOGRAPHY | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.